Myqorzo (aficamten) is a new therapy for oHCM, improving functional capacity and symptoms, with an annual cost of $108,400. The Myqorzo & You program provides personalized support, including insurance ...
February is a time to honor every heartbeat—our own and the hearts of those we love. Professionally, it’s a reminder of the ...
Brandon Buckingham suffered multiple organ failure last year due to tuberculosis. Buckingham shared that his liver, kidney, and pancreas have fully recovered, but he is still in heart failure.
A heart murmur can sound scary—literally. A Keck Medicine of USC cardiologist explains why it might not be as scary as you ...
Ray J has opened up about his treatment after experiencing heart issues ...
Background Congenital heart disease (CHD) is the leading congenital cause of death in newborns worldwide. Approximately ...
MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCMSOUTH SAN FRANCISCO, Calif., ...
Whether heart failure develops and how it progresses depends not only on physical factors, but also on external influences ...
The 2026 American Heart Association Heart Disease and Stroke Statistics report shows that nearly half of adults are living ...
Background Aortic stenosis (AS) frequently coexists with heart failure (HF), but its prevalence, prognostic impact and management across the full HF spectrum remain incompletely characterised. Methods ...
When an older patient is admitted with pneumonia, a urinary tract infection (UTI), or shingles, clinicians rightly focus on stabilisation, antibiotics, and discharge planning. Yet what may unfold in ...
Nancy Preston didn’t have a heart attack. Nor did she have chest discomfort, shortness of breath or heart palpitations — all symptoms of heart disease. Instead, a routine mammogram led to Preston ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results